The estimated Net Worth of Kenneth Krogulski is at least $277 Thousand dollars as of 1 December 2022. Mr. Krogulski owns over 3,050 units of Cumberland Pharmaceuticals stock worth over $276,710 and over the last 8 years he sold CPIX stock worth over $0. In addition, he makes $0 as Independent Director at Cumberland Pharmaceuticals.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Krogulski CPIX stock SEC Form 4 insiders trading
Kenneth has made over 21 trades of the Cumberland Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,050 units of CPIX stock worth $6,771 on 1 December 2022.
The largest trade he's ever made was buying 15,000 units of Cumberland Pharmaceuticals stock on 21 March 2017 worth over $97,950. On average, Kenneth trades about 1,489 units every 52 days since 2017. As of 1 December 2022 he still owns at least 204,955 units of Cumberland Pharmaceuticals stock.
You can see the complete history of Mr. Krogulski stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kenneth Krogulski biography
Kenneth J. Krogulski, is an Independent Director of the Company. He has over 40 years of experience in security analysis and portfolio management and is currently the President and Chief Executive Officer of Berkshire Asset Management, LLC, as well as the company’s Chief Investment Officer. Berkshire is a 33-year-old independent SEC registered Pennsylvania based investment advisory firm with over $2.2 billion in assets under supervision. Prior to Berkshire, Mr. Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department. He then joined Berkshire in 1990 and later led a management buy-out acquiring the company from Legg Mason. Under his leadership Berkshire’s assets under supervision have grown from $600 million in 2006 and are now over $2.2 billion. Currently Mr. Krogulski serves on the board of Allied Services Rehabilitation Hospital and is a Director of Landmark Community Bank (LDKB: NASDAQ). Previously he served as the Director of the Wyoming Valley Health Care System, on the board of the F.M. Kirby Center for the Performing Arts, the Luzerne Foundation and on various other community boards. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation. The Board of Directors believes Mr. Krogulski's extensive financial background and public company investing experience will be critical to supporting the Company's financing strategy.
How old is Kenneth Krogulski?
Kenneth Krogulski is 63, he's been the Independent Director of Cumberland Pharmaceuticals since 2017. There are 12 older and 6 younger executives at Cumberland Pharmaceuticals. The oldest executive at Cumberland Pharmaceuticals Inc. is Jonathan Griggs, 85, who is the Independent Director.
What's Kenneth Krogulski's mailing address?
Kenneth's mailing address filed with the SEC is 1600 WEST END AVE., SUITE 1300, , NASHVILLE, TN, 37203.
Insiders trading at Cumberland Pharmaceuticals
Over the last 15 years, insiders at Cumberland Pharmaceuticals have traded over $4,393,644 worth of Cumberland Pharmaceuticals stock and bought 265,077 units worth $1,208,228 . The most active insiders traders include Joey A Jacobs, Leo Pavliv, and Thomas R Lawrence. On average, Cumberland Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $10,407. The most recent stock trade was executed by Caroline Young on 1 December 2022, trading 379 units of CPIX stock currently worth $849.
What does Cumberland Pharmaceuticals do?
cumberland pharmaceuticals is a specialty pharmaceutical company whose mission is to acquire currently marketed and late-stage development pharmaceutical products and grow them through marketing to targeted, underserved physician segments. cumberland is dedicated to providing high quality products which address unmet medical needs.
What does Cumberland Pharmaceuticals's logo look like?
Complete history of Mr. Krogulski stock trades at Cumberland Pharmaceuticals
Cumberland Pharmaceuticals executives and stock owners
Cumberland Pharmaceuticals executives and other stock owners filed with the SEC include:
-
A. Kazimi,
Chairman of the Board, Chief Executive Officer -
A. J. Kazimi,
Founder, Chairman, Pres & CEO -
Leo Pavliv,
Executive Vice President - Operations, Chief Development Officer -
Leo B. Pavliv,
Exec. VP of Operations & Chief Devel. Officer -
Martin Cearnal,
Executive Vice President, Chief Commercial Officer, Director -
Martin E. Cearnal,
Exec. VP, Chief Commercial Officer & Director -
James Herman,
Vice President - National Accounts, Chief Compliance Officer -
James Lowrance Herman,
Sr. VP of National Accounts & Chief Compliance Officer -
Michael Bonner,
Senior Director Finance and Accounting and Chief Financial Officer -
Caroline Young,
Independent Director -
Kenneth Krogulski,
Independent Director -
James Jones,
Independent Director -
Joey Jacobs,
Independent Director -
Jonathan Griggs,
Independent Director -
Joseph Galante,
Independent Director -
Gordon Bernard,
Independent Director -
Erin Smith Gull,
Sr. Corp. Relations Associate -
Adam S. Mostafa,
Managing Director -
Cindy B. Patton,
Sr. Director of Field Marketing -
Jean W. Marstiller,
Sr. VP of Admin. Services & Corp. Sec. -
John Michael Hamm,
Director of Fin. & Accounting and CFO -
Thomas R Lawrence,
Director -
Martin S Jr Brown,
-
Chris T. Bitterman,
Vice Pres Sales & Marketing -
Rick Scott Greene,
Chief Financial Officer -
Robert Edwards,
Director -
Jean W Marstiller,
Sr. VP & Corp. Secretary -
Lawrence W Greer,
Director -
David L Lowrance,
Vice President and CFO -
Todd M. Anthony,
Vice Pres Organizational Dev -
John M. Hamm,
VP Chief Financial Officer